BARCLAYS PLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 420 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$23,186
+10.7%
510,832
+36.9%
0.01%
+7.7%
Q2 2023$20,953
+0.3%
373,203
-19.2%
0.01%
+30.0%
Q1 2023$20,884
+12.6%
461,759
+1.2%
0.01%
+25.0%
Q4 2022$18,547
-99.7%
456,277
+319.5%
0.01%0.0%
Q3 2022$7,108,000
+439.7%
108,766
+402.4%
0.01%
+700.0%
Q2 2022$1,317,000
+19.0%
21,649
+22.8%
0.00%0.0%
Q1 2022$1,107,000
-48.4%
17,624
-37.8%
0.00%
Q4 2021$2,146,000
-42.0%
28,342
-14.2%
0.00%
-100.0%
Q3 2021$3,697,000
+8.7%
33,030
+57.1%
0.00%0.0%
Q2 2021$3,402,000
+381.9%
21,024
+262.5%
0.00%
Q1 2021$706,000
-81.4%
5,800
-76.6%
0.00%
-100.0%
Q4 2020$3,789,000
+239.2%
24,747
+85.3%
0.00%
+100.0%
Q3 2020$1,117,000
+13862.5%
13,357
+11933.3%
0.00%
Q2 2020$8,000
+33.3%
111
-25.0%
0.00%
Q1 2020$6,000
-98.1%
148
-97.2%
0.00%
Q4 2019$324,000
-43.0%
5,309
-61.7%
0.00%
Q3 2019$568,000
+23.7%
13,877
+42.7%
0.00%
Q2 2019$459,000
-13.1%
9,726
-34.3%
0.00%
Q1 2019$528,000
+279.9%
14,799
+203.3%
0.00%
Q4 2018$139,000
-74.3%
4,879
-59.9%
0.00%
Q3 2018$541,000
-87.9%
12,181
-84.0%
0.00%
-100.0%
Q2 2018$4,481,000
+35.1%
76,271
+5.1%
0.00%
+33.3%
Q1 2018$3,318,000
+821.7%
72,600
+374.5%
0.00%
Q4 2017$360,000
+70.6%
15,300
+29.0%
0.00%
Q3 2017$211,00011,8640.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q2 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders